Dynavax Awarded $3 Million Universal Flu Vaccine Grant From NIAID

Dynavax Technologies Corporation announced that the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH), has awarded a two-year $3.25 million grant to continue development of a novel universal influenza vaccine for controlling seasonal and emerging pandemic flu strains.
Dynavax Technologies